Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atro

Annexon (ANNX) announced the appointment of Lloyd Clark, M.D., as Senior Vice President, Ophthalmology Strategy and Innovation, to advance their ANX007 program for dry age-related macular degeneration (AMD) with geographic atrophy (GA). ANX007 is currently in a Phase 3 trial (ARCHER II) with enrollment expected to complete in Q3 2025 and topline data anticipated in the second half of 2026; it is the only investigational therapy shown to significantly preserve vision in GA patients. Dr. Clark's expertise is expected to be pivotal in the strategic development and execution of Annexon's ophthalmology program.

Analysis

Annexon, Inc. (ANNX) has significantly bolstered its ophthalmology division with the appointment of Dr. Lloyd Clark, a highly experienced retina specialist with 25 years in the field and involvement as a principal investigator in over 70 clinical trials, to the role of Senior Vice President, Ophthalmology Strategy and Innovation. This strategic hire aims to advance ANX007, Annexon's investigational therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA), a condition affecting over eight million individuals globally with no currently approved therapies that preserve vision. ANX007, a non-pegylated antigen-binding fragment designed to block C1q, is uniquely positioned as the only investigational program to have demonstrated significant preservation of vision (measured by BCVA and LLVA) and central retinal photoreceptors in GA patients. The ongoing global, pivotal Phase 3 ARCHER II trial is expected to complete enrollment in Q3 2025, with crucial topline data anticipated in the second half of 2026. This development, coupled with a strongly positive sentiment score of 0.8 for the company, highlights Annexon's potential to address a substantial unmet medical need, contingent upon successful Phase 3 outcomes for ANX007, which targets a well-established functional endpoint for regulatory approval.

Key Decisions for Investors

• Investors should consider the long-term potential of ANNX, given ANX007's unique mechanism and first-in-class potential in the large GA market, while acknowledging the inherent clinical trial risks with key data expected in H2 2026.
• Monitor the progress of the Phase 3 ARCHER II trial, particularly the completion of enrollment in Q3 2025, as this timeline adherence is crucial for the anticipated data release and subsequent regulatory milestones.
• Evaluate Annexon's positioning relative to competitors in the GA space, as the success of ANX007 will depend not only on its clinical efficacy but also on the evolving therapeutic landscape for this leading cause of blindness.